prIME Decision Points: Navigating the Treatment Landscape for Chronic Lymphocytic Leukemia - priME Oncology
prIME Decision Points
prIME Decision Points

prIME Decision Points: Navigating the Treatment Landscape for Chronic Lymphocytic Leukemia

Not a member of My prIME? Join now for instant access.

prIME Decision Points: Navigating the Treatment Landscape for Chronic Lymphocytic Leukemia

View Activity

Activity Overview

This CME-certified online activity includes two clinical scenarios that mimic the patient encounter in the clinic. Each case includes patient histories, laboratory results, and options for the next step in treatment. At each decision point, expert faculty provide commentary and insight. The cases focus on the management and treatment of patients diagnosed with chronic lymphocytic leukemia (CLL) including: front-line treatment, the role of minimal residual disease (MRD), the relapsed/refractory patient, and managing older patients. A link to and a downloadable PDF of the FACIT patient assessment tool, FACT-Leu, specifically designed for patients with leukemia is also provided.

The FACIT Measurement System is a collection of quality of life (QOL) questionnaires targeted to the management of chronic illness. The questionnaires were developed using four primary QOL domains:

  • Physical Well-Being
  • Social/Family Well-Being
  • Emotional Well-Being
  • Functional Well-Being

The questionnaires have been developed and validated for specific disease types: cancer, HIV/AIDS and Multiple Sclerosis. See www.FACIT.org for additional information.

View Activity

Provider

This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
accme

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This educational activity is supported by a grant from Genentech.

Case Scenario 1

Case Scenario 2